Genentech CEO and leadership

Alexander Hardy is the CEO of Genentech.

Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Ed Harrington is Genentech’s chief financial officer. He assumed this role in January 2016. Ed leads the Genentech and Pharma North America Finance organizations as well as the Genentech Site Services function. He is a member of the Genentech Executive Committee and the Global Pharma Finance Leadership Team.

Ed joined Roche in 2001 as finance director, U.S. Consumer Health in Nutley, New Jersey. Following this role, he was finance director, US Pharma Alliances, General and Administrative, Tech Services, IT in New Jersey from 2003-2006. Ed moved to Switzerland in 2006 as global head of Pharma Strategic Alliances and R&D Portfolio Controlling through 2009. He then joined Roche Canada as vice president and chief financial officer from 2010-2012.

In 2013, Ed moved to Roche China where he was vice president, Finance. In this role he was responsible for Finance, Procurement and Business Development.

Prior to joining Roche, Ed held both finance and accounting positions in companies including J. P. Morgan and Ernst & Young.

Ed received his bachelor's degree in accounting from Robert Morris University and an MBA in finance and international business management from Carnegie Mellon University.

Dr. Levi Garraway, MD, PhD, presently serves as EVP, Head of Product Development, and Chief Medical Officer at Genentech and Roche, a position he has held since 2019. He was most recently Eli Lilly’s Senior Vice President, Oncology Research and Development & Lilly Research Laboratories Novel Target Research. He joined Eli Lilly in 2017 as Senior Vice President, Global Development and Medical Affairs for their Oncology division. Prior to that, Dr. Garraway was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. He was

also co-leader of the Cancer Genetics Program at the Dana-Farber / Harvard Cancer Center. In

2010, Dr. Garraway co-founded Foundation Medicine, the world’s leading provider of tumor

molecular information. A Fellow of the American Association for Cancer Research (AACR), over the course of his career Dr. Garraway has served on the advisory boards of major cancer centers including Memorial Sloan Kettering and MD Anderson. He also served on several major National Institutes of Health (NIH) committees as well as the Blue Ribbon Panel for the Beau Biden Cancer Moonshot Initiative. Dr. Garraway was president of the American Society of Clinical Investigation from 2014 - 2015. He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the

Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the AACR, the New

Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute. Dr. Garraway is a graduate of Harvard, where he earned his A.B., M.D., and his Ph.D. in Biological Chemistry and Molecular Pharmacology.

Alexander Hardy is the CEO of Genentech.

Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Dr. Levi Garraway, MD, PhD, presently serves as EVP, Head of Product Development, and Chief Medical Officer at Genentech and Roche, a position he has held since 2019. He was most recently Eli Lilly’s Senior Vice President, Oncology Research and Development & Lilly Research Laboratories Novel Target Research. He joined Eli Lilly in 2017 as Senior Vice President, Global Development and Medical Affairs for their Oncology division. Prior to that, Dr. Garraway was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. He was

also co-leader of the Cancer Genetics Program at the Dana-Farber / Harvard Cancer Center. In

2010, Dr. Garraway co-founded Foundation Medicine, the world’s leading provider of tumor

molecular information. A Fellow of the American Association for Cancer Research (AACR), over the course of his career Dr. Garraway has served on the advisory boards of major cancer centers including Memorial Sloan Kettering and MD Anderson. He also served on several major National Institutes of Health (NIH) committees as well as the Blue Ribbon Panel for the Beau Biden Cancer Moonshot Initiative. Dr. Garraway was president of the American Society of Clinical Investigation from 2014 - 2015. He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the

Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the AACR, the New

Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute. Dr. Garraway is a graduate of Harvard, where he earned his A.B., M.D., and his Ph.D. in Biological Chemistry and Molecular Pharmacology.

Frederick (Rick) Kentz, serves as the Chief Compliance Officer, Senior Vice President, Secretary and Head of Legal Affairs - North America at Genentech, Inc. Kentz has been a Director of Roche Holdings, Inc. since December 2, 2008 and Director of Anadys Pharmaceuticals Inc. since November 23, 2011.